NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Care Facilities · USD

biote Corp. (BTMD) Stock Analysis

biote Corp. (BTMD) is a Medical Care Facilities stock listed on NASDAQ and quoted in US Dollar.

BTMD

$1.55

−$0.01 (−0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BTMD with… →

BTMD Key Statistics

As of Sep 4, 2026
Trading
Open
$1.55
Previous Close
$1.55
Day's Range
1.52–1.60
52-Week Range
1.27–3.58
Volume
77.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.61
Valuation
Market Cap
$52.37M
P/E Ratio
11.04
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.43
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.29
EPS (ttm)Profit attributable to each share over the last twelve months.
0.14
Financials (FY)
Revenue (FY)
$192.22M−2.52%
Net Income (FY)
$27.05M+756.67%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
28.68M
1-Year Return
−54.42%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
328.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BTMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−40.58%
2025−57.93%
2024+25.10%
2023+32.44%
2022−61.94%
2021 (partial year)−2.49%

As of September 4, 2026.

BTMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$192.22M$27.05M14.1%
2024$197.19M$3.16M1.6%
2023$185.36M$3.32M1.8%
2022$164.96M−$969.00K−0.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$192.22M$137.36M$35.55M$27.05M14.1%
2024$197.19M$139.06M$31.61M$3.16M1.6%
2023$185.36M$127.48M$28.66M$3.32M1.8%
2022$164.96M$110.38M−$60.72M−$969.00K−0.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BTMD Valuation vs Medical Care Facilities Median

Median of 57 stocks
MetricBTMDMedical Care Facilities medianvs median
P/E11.0419.8444% below
P/S ratio0.290.950.3x the median
Profit margin3.19%3.06%0.1 pts above

Medians across 57 Medical Care Facilities stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

biote Corp. (BTMD) carries a market capitalisation of $52.37M. The company sits in the Healthcare sector, in the Medical Care Facilities industry. Headcount on file is 223.

BTMD last closed at $1.55 on September 4, 2026. That is −$0.01 (−0.32%) against the previous close. The 52-week range on file runs from $1.27 to $3.58. The latest close sits 21.65% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $192.22M. Against the prior fiscal year total of $197.19M, that is a change of −2.52%. The same year closed with net income of $27.05M. That is +756.67% against the prior fiscal year. The reported profit margin is 3.19%. That is 0.1 percentage points above the Medical Care Facilities median of 3.06%. Trailing earnings per share are 0.14.

Across the 4 fiscal years on file, revenue moves from $164.96M in 2022 to $192.22M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 11.04. That is 44.35% below the Medical Care Facilities median of 19.84. On forward earnings the ratio is 3.43. Measured against sales, the shares trade at 0.29 times revenue. On price-to-sales that is 0.3 times the Medical Care Facilities median of 0.95. The medians here are taken across 57 Medical Care Facilities companies that report the metric.

The trailing one-year price return is −54.42%. Across 5 years the annualized return works out at −30.68%. The reported beta is 1.61. Annualized volatility over the trailing 5 years is 70.62%.

Growth & Income

No dividend is on file for BTMD.

2026 is still running; the price is −40.58% year to date. Across the complete calendar years on file, 2023 returned +32.44% and 2022 returned −61.94%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

biote Corp. (BTMD) operates in the Medical Care Facilities industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
biote Corp. BTMD $52.37M 11.0
HCA Healthcare, Inc. HCA $87.68B 13.6
Tenet Healthcare Corporation THC $21.34B 10.2
Fresenius Medical Care AG FMS $12.06B 11.7

The Medical Care Facilities industry average P/E ratio is 19.8x. biote Corp. trades at a P/E of 11.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Care Facilities Stocks

HCA

HCA Healthcare, Inc.

$87.68B

 THC

Tenet Healthcare Corporation

$21.34B

 FMS

Fresenius Medical Care AG

$12.06B

 EHC

Encompass Health Corporation

$12.01B

 DVA

DaVita Inc.

$11.74B

 UHS

Universal Health Services, Inc.

$10.00B
View all Medical Care Facilities stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About biote Corp.

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

Visit website →